✦ LIBER ✦

Complete Response of Relapsed Systemic and Cutaneous Anaplastic Large Cell Lymphoma Using Brentuximab Vedotin: 2 Case Reports

✍ Scribed by Broccoli, Alessandro; Derenzini, Enrico; Pellegrini, Cinzia; Narducci, Riccardo; Stefani, Giulia; Casadei, Beatrice; Argnani, Lisa; Zinzani, Pier Luigi

Book ID: 120391245
Publisher: Elsevier
Year: 2013
Tongue: English
Weight: 111 KB
Volume: 13
Category: Article
ISSN: 2152-2650
DOI: 10.1016/j.clml.2013.03.008

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Resolution of malignant cutaneous lesion

Resolution of malignant cutaneous lesions with brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large cell lymphoma

📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Efficacy of Brentuximab Vedotin and Othe

Efficacy of Brentuximab Vedotin and Other Treatments in Patients with Relapsed or Refractory (RR) Systemic Anaplastic Large-Cell Lymphoma (SALCL): A Systematic Review

✍ Bonthapally, V.; Yang, H.; Macalalad, A.R.; Wu, E.Q.; Lutes, R.; Shonukan, O.; C 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 61 KB

Brentuximab Vedotin: A Review of Its Use

Brentuximab Vedotin: A Review of Its Use in Patients with Hodgkin Lymphoma and Systemic Anaplastic Large Cell Lymphoma Following Previous Treatment Failure

✍ Garnock-Jones, Karly P. 📂 Article 📅 2013 🏛 Springer International Publishing AG 🌐 English ⚖ 469 KB

Brentuximab vedotin in Hodgkin lymphoma

Brentuximab vedotin in Hodgkin lymphoma and systemic anaplastic large-cell lymphoma: The FDA approval of this novel antibody-drug conjugate is based on durable responses, with no data yet showing improved survival

✍ Jame Abraham 📂 Article 📅 2012 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 108 KB